A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer

被引：0
|
作者：
Iwama, E. [1 ]
Sakai, K. [2 ]
Azuma, K. [3 ]
Nosaki, K. [4 ]
Harada, D. [5 ]
Hotta, K. [6 ]
Ohyanagi, F. [7 ]
Kurata, T. [8 ]
Akamatsu, H. [9 ]
Goto, K. [10 ]
Fukuhara, T. [11 ]
Nakanishi, Y. [1 ]
Nishio, K. [2 ]
Okamoto, I. [1 ]
机构：
[1] Kyushu Univ, Res Inst Dis Chest, Fukuoka 812, Japan
[2] Kinki Univ, Sch Med, Dept Genome Biol, Osakasayama, Japan
[3] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Fukuoka, Japan
[4] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan
[5] Shikoku Canc Ctr, Dept Thorac Oncol, Matsuyama, Ehime, Japan
[6] Okayama Univ Hosp, Resp Med, Okayama, Japan
[7] Canc Inst Hosp JFCR, Dept Thorac Med Oncol, Tokyo, Japan
[8] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan
[9] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[10] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan
[11] Miyagi Canc Ctr, Dept Resp Med, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
484PD
引用
收藏
页码：148 / 149
页数：2
相关论文
共 50 条
  • [41] EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib
    Winther-Larsen, Anne
    Ebert, Eva Boysen Fynboe
    Meldgaard, Peter
    Sorensen, Boe Sandahl
    CLINICAL LUNG CANCER, 2019, 20 (03) : 161 - +
  • [42] Clinical outcome of treatment with pemetrexed/cisplatin in patients with EGFR-mutation negative (EGFR-) metastatic non-small cell lung cancer (NSCLC)
    Storozhakova, Anna E.
    Vladimirova, Liubov Yu
    Kit, Oleg Ivanovich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Igawa, Satoshi
    Kasajima, Masashi
    Ono, Taihei
    Ozawa, Takahiro
    Kakegawa, Mikiko
    Kusuhara, Seiichiro
    Sato, Takashi
    Nakahara, Yoshiro
    Fukui, Tomoya
    Yokoba, Masanori
    Kubota, Masaru
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8695 - 8705
  • [44] Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group
    Sonehara, Kei
    Kobayashi, Takashi
    Tateishi, Kazunari
    Morozumi, Nobutoshi
    Yoshiike, Fumiaki
    Hachiya, Tsutomu
    Ono, Yasushi
    Takasuna, Keiichirou
    Agatsuma, Toshihiko
    Masubuchi, Takeshi
    Matsuo, Akemi
    Tanaka, Hozumi
    Morikawa, Akio
    Hanaoka, Masayuki
    Koizumi, Tomonobu
    THORACIC CANCER, 2019, 10 (05) : 1078 - 1085
  • [45] Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study
    Maezawa, Yosuke
    Taguchi, Manato
    Kawakami, Takeshi
    Inui, Toshihide
    Okauchi, Shinichiro
    Numata, Takeshi
    Shiozawa, Toshihiro
    Miyazaki, Kunihiko
    Nakamura, Ryota
    Iguchi, Kesato
    Endo, Takeo
    Sakamoto, Tohru
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2024, 44 (04) : 1751 - 1757
  • [46] Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer with Four Structure-Based EGFR-Mutation Subgroups
    Gu, L.
    Yu, Y.
    Shen, L.
    Yao, F.
    Zhu, C.
    Wang, J.
    Lu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S603 - S604
  • [47] Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study)
    Morikawa, Kei
    Takata, Saori
    Tanaka, Hisashi
    Horiuchi, Kazuya
    Okuma, Yusuke
    Soejima, Kenzo
    Nakagawa, Hideyuki
    Nakahara, Yoshiro
    Seki, Yoshitaka
    Bessyo, Akihiro
    Takahashi, Nobumasa
    Hayashi, Kentaro
    Endo, Takeo
    Takeyama, Ren
    Maekura, Toshiya
    Takigawa, Nagio
    Horimoto, Katsuhisa
    Matsutani, Noriyuki
    Seki, Nobuhiko
    ANNALS OF ONCOLOGY, 2023, 34 : S1418 - S1419
  • [48] A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
    Noro, R.
    Igawa, S.
    Bessho, A.
    Hirose, T.
    Tsuneo, S.
    Nakashima, M.
    MInato, K.
    Seki, N.
    Tokito, T.
    Harada, T.
    Sasada, S.
    Miyamoto, S.
    Tanaka, Y.
    Furuya, N.
    Kaburagi, T.
    Hayashi, H.
    Iihara, H.
    Naoki, K.
    Okamoto, H.
    Kubota, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S872 - S873
  • [49] A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
    Igawa, S.
    Noro, R.
    Kubota, K.
    Naoki, K.
    Bessho, A.
    Hirose, T.
    Shimokawa, T.
    Nakashima, M.
    Minato, K.
    Seki, N.
    Tokito, T.
    Harada, T.
    Sasada, S.
    Miyamoto, S.
    Tanaka, Y.
    Furuya, N.
    Kaburagi, T.
    Hayashi, H.
    Lihara, H.
    Okamoto, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1399 - S1400
  • [50] Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
    van Veggel, B.
    Santos, J. F. Vilacha Madeira R.
    Hashemi, S. M. S.
    Paats, M. S.
    Monkhorst, K.
    Heideman, D. A. M.
    Groves, M.
    Radonic, T.
    Smit, E. F.
    Schuuring, E.
    van der Wekken, A. J.
    de Langen, A. J.
    LUNG CANCER, 2020, 141 : 9 - 13
12345